Crestor vs Repatha: Titration Speed and Tolerability Compared

How Each Drug Lowers LDL

Rosuvastatin blocks HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, forcing liver cells to upregulate LDL receptors. Evolocumab binds and inhibits PCSK9, a protein that would otherwise tag those same LDL receptors for destruction. The two mechanisms are complementary rather than redundant, which is why combining them produces additive LDL lowering far beyond what either drug achieves alone. A 2022 meta-analysis in the European Heart Journal confirmed that PCSK9 inhibitors added to statin therapy reduce LDL by an additional 54 to 60% beyond the statin baseline.

Rosuvastatin Mechanism and Potency

Rosuvastatin is a synthetic, hydrophilic statin with the highest receptor-binding affinity in its class. At 40 mg daily, it reduces LDL by up to 63%, making it the most potent oral statin approved by the FDA. The FDA label for rosuvastatin notes dose-dependent LDL reductions of 45% at 10 mg, 52% at 20 mg, and 55 to 63% at 40 mg.

Evolocumab Mechanism and Potency

Evolocumab is a fully human monoclonal antibody targeting PCSK9. It does not require receptor agonism or enzymatic inhibition. Instead, it removes the "destruction signal" from LDL receptors so they cycle back to the hepatocyte surface and continue clearing LDL from plasma. In the FOURIER trial (N=27,564), evolocumab reduced LDL from a median of 92 mg/dL to 30 mg/dL, a 59% reduction, at 48 weeks, with effects sustained through 2.2 years of follow-up.

Titration Speed: The Core Practical Difference

This is where the two drugs diverge most sharply in clinical practice. Rosuvastatin requires a structured titration protocol. Evolocumab does not.

Rosuvastatin Titration Protocol

Prescribers typically start rosuvastatin at 5 to 10 mg daily in statin-naive patients, then recheck a fasting lipid panel at 4 to 6 weeks. If the LDL goal is not met, the dose advances to 20 mg, with another lipid panel at 4 to 6 weeks. Patients needing maximum LDL reduction move to 40 mg, with a final check at 4 to 6 weeks.

The full titration process from start to confirmed therapeutic dose takes 8 to 12 weeks in patients who need two dose increases. ACC/AHA 2018 guidelines on blood cholesterol management recommend reassessing lipids 4 to 12 weeks after initiating or titrating statin therapy.

That 8 to 12 week lag matters in post-ACS patients whose risk is highest in the first 90 days after an event.

Evolocumab Titration Protocol

There is no titration protocol. The approved dosing is 140 mg subcutaneously every 2 weeks or 420 mg subcutaneously once monthly, and both regimens produce equivalent LDL lowering. The FDA-approved prescribing information for evolocumab confirms that no dose adjustment is needed based on baseline LDL, renal function, or mild-to-moderate hepatic impairment.

The first injection reduces LDL by approximately 60% within 2 weeks. For a patient who has just survived a myocardial infarction, that speed has real clinical value.

Why Titration Speed Matters Clinically

Higher residual LDL during titration translates directly to continued atherosclerotic plaque formation. The Mendelian randomization data from a 2016 JAMA Cardiology analysis suggested that each 38.7 mg/dL lifetime reduction in LDL from birth is associated with a 54.5% lower risk of coronary heart disease. See the full analysis here. Getting to target faster is not a cosmetic advantage.

Tolerability Profiles Head to Head

Both drugs are generally well tolerated, but the nature of their side-effect profiles differs substantially.

Muscle-Related Side Effects With Rosuvastatin

Myalgia, defined as muscle pain without CK elevation, is the most clinically common statin side effect. Observational data from the PRIMO registry (N=7,924 statin-treated patients) found that 10.5% of patients on high-intensity statins reported muscle symptoms. PRIMO registry results are summarized in Cardiovascular Drugs and Therapy, available at PubMed.

True statin-induced myopathy (CK >10x upper limit of normal with symptoms) is rare, occurring in fewer than 1 per 10,000 patient-years. Rhabdomyolysis is rarer still. Rosuvastatin's hydrophilic profile makes it less likely than lipophilic statins (atorvastatin, simvastatin) to penetrate muscle tissue, but myalgias still occur in a clinically meaningful proportion of patients on 40 mg daily.

Muscle-Related Side Effects With Evolocumab

In FOURIER (N=27,564), the rate of myalgia was 2.6% in the evolocumab arm versus 2.7% in placebo. The full FOURIER safety data are published in the New England Journal of Medicine. Evolocumab has no direct mechanism for causing myopathy. When patients on background statin therapy report new myalgias after starting evolocumab, the statin is almost always the causative agent.

Injection-Site Reactions With Evolocumab

Evolocumab is injected subcutaneously. Injection-site reactions (redness, bruising, pain) occurred in 3.2% of FOURIER participants receiving evolocumab versus 2.9% placebo. These reactions were mild and did not drive discontinuation at meaningful rates.

Hepatic and Renal Safety

Rosuvastatin carries a class-level warning for transaminase elevation; clinically significant hepatotoxicity is rare (<1%) but the FDA label recommends a baseline LFT before initiating therapy. Evolocumab does not require routine hepatic monitoring. Neither drug requires dose adjustment for moderate renal impairment, though rosuvastatin should be capped at 10 mg daily in severe chronic kidney disease (eGFR <30 mL/min/1.73m²). The rosuvastatin prescribing information details renal dosing adjustments.

Cognitive and Neuromuscular Concerns

A 2019 FDA review found no causal evidence linking PCSK9 inhibitors to cognitive decline despite an early pharmacovigilance signal. The FDA communication on PCSK9 inhibitors and cognition is available on the FDA website. Statins carry a label warning for rare cases of memory impairment, but prospective cognitive data from FOURIER and the ODYSSEY OUTCOMES trial showed no excess cognitive adverse events with PCSK9 inhibition.

Cardiovascular Outcomes Data

JUPITER Trial: Rosuvastatin in Primary Prevention

The JUPITER trial enrolled 17,802 apparently healthy adults with LDL <130 mg/dL but elevated high-sensitivity CRP (>2 mg/L). Rosuvastatin 20 mg daily reduced the primary composite endpoint (MI, stroke, arterial revascularization, hospitalization for unstable angina, or CV death) by 44% versus placebo (HR 0.56; 95% CI 0.46 to 0.69; P<0.00001). JUPITER was published in the New England Journal of Medicine in 2008.

The trial was stopped early at a median follow-up of 1.9 years because the benefit was so clear. New-onset diabetes was modestly increased in the rosuvastatin arm (3.0% vs. 2.4%, P=0.01), a risk replicated across statin trials and now included in the FDA label.

FOURIER Trial: Evolocumab in Secondary Prevention

FOURIER enrolled 27,564 patients with established atherosclerotic cardiovascular disease already on statin therapy. Evolocumab added on top of statin reduced the key secondary endpoint (CV death, MI, or stroke) by 20% (HR 0.80; 95% CI 0.73 to 0.88; P<0.001). Full FOURIER results are in the New England Journal of Medicine.

The primary composite endpoint (including revascularization and unstable angina hospitalization) was reduced by 15%. Absolute risk reduction for the key secondary endpoint was 1.5 percentage points over 2.2 years, translating to a number needed to treat of 67.

What the Trials Cannot Tell You Directly

Neither JUPITER nor FOURIER compared rosuvastatin head to head against evolocumab. They enrolled different populations under different background therapies, so cross-trial relative risk comparisons are unreliable. The ACC/AHA 2018 guidelines explicitly state that PCSK9 inhibitors are additive to, not replacements for, statin therapy in most patients. See ACC/AHA guideline statement in Circulation.

When Should You Switch From Crestor to Repatha, or Combine Both?

This is the most frequently asked clinical question from patients whose LDL remains above goal on rosuvastatin alone.

Situations Where Adding Repatha Makes Sense

Patients with heterozygous familial hypercholesterolemia (HeFH) on maximum-tolerated statin often still have LDL above 100 mg/dL. The ACC/AHA 2018 guidelines recommend considering a PCSK9 inhibitor when LDL remains >100 mg/dL despite maximally tolerated statin plus ezetimibe in patients with clinical ASCVD or HeFH. The guideline algorithm is detailed in the 2018 Cholesterol Guideline published in Circulation.

Post-ACS patients represent the other major group. If LDL remains above 70 mg/dL at 4 to 6 weeks post-discharge on rosuvastatin 40 mg, adding evolocumab (rather than waiting for further titration) delivers faster and deeper LDL lowering during the highest-risk recovery window.

Situations Where Switching Makes Sense

True statin intolerance, documented by recurrent myalgia on two separate statins with symptom resolution on drug holiday, is the clearest indication to replace rosuvastatin with evolocumab. A 2021 European Atherosclerosis Society consensus paper defined statin intolerance and recommended PCSK9 inhibitors as primary alternatives.

Switching, rather than adding, is appropriate when the statin is genuinely not tolerated and the patient lacks the cardiovascular risk profile that justifies the additive benefit of combination therapy.

Cost and Prior Authorization Barriers

Evolocumab carries a list price near $7,200 per year in the United States, versus roughly $20 to 40 per year for generic rosuvastatin. Most payers require documented statin intolerance or a prior LDL above a specified threshold (commonly 100 mg/dL on maximally tolerated statin therapy) before authorizing Repatha. Patients should expect a prior authorization process of 1 to 4 weeks, which itself adds time before the drug's fast-acting LDL reduction can begin.

A practical decision framework used by the HealthRX clinical team:

1. Start rosuvastatin 10 to 20 mg. Recheck LDL at 6 weeks.
2. If LDL >100 mg/dL in ASCVD or >130 mg/dL in primary prevention, uptitrate to 40 mg. Recheck at 6 weeks.
3. If still above goal after 40 mg (or patient reports reproducible myalgia), add ezetimibe 10 mg. Recheck at 4 weeks.
4. If LDL remains >70 mg/dL (ASCVD) or >100 mg/dL (HeFH), initiate prior authorization for evolocumab 140 mg SC q2 weeks.
5. Document response at 8 weeks post-first Repatha injection. At that point, the LDL result reflects true steady-state inhibition.

Practical Dosing and Monitoring Comparison

Rosuvastatin Dosing Summary

• Starting dose: 5 to 10 mg daily (statin-naive or elderly patients); 20 mg daily in patients with known ASCVD who need rapid LDL lowering.
• Target dose for high-intensity therapy: 20 to 40 mg daily.
• Monitoring: fasting lipid panel at 4 to 6 weeks after each dose change; baseline CK in patients with risk factors for myopathy; ALT at baseline.
• Drug interactions: cyclosporine (contraindicated at doses >5 mg); antacids reduce absorption by ~54% when co-administered.

Evolocumab Dosing Summary

• Dosing options: 140 mg SC every 2 weeks (autoinjector pen or prefilled syringe) or 420 mg SC once monthly (three consecutive 140 mg injections within 30 minutes using Pushtronex on-body infusor).
• Monitoring: lipid panel 4 to 8 weeks after initiation to confirm response; no routine hepatic or renal labs required by prescribing information.
• Storage: refrigerated at 36 to 46°F; can be stored at room temperature up to 77°F for up to 30 days.
• No dose adjustment for age, sex, body weight, or mild-to-moderate renal or hepatic impairment.

Special Populations

Patients With Diabetes

Statin therapy modestly increases fasting glucose. In JUPITER, new-onset diabetes occurred in 270 rosuvastatin-treated patients versus 216 placebo patients over 1.9 years. These data are reported in the original JUPITER publication in the New England Journal of Medicine. The absolute risk increase was 0.6%, which the ACC/AHA consider offset by cardiovascular benefit in patients with elevated CV risk.

Evolocumab showed no effect on glycemic parameters in FOURIER. Patients with diabetes managed on rosuvastatin who develop worsening glycemic control should discuss this trade-off explicitly with their prescriber rather than discontinuing the statin without a replacement plan.

Elderly Patients

Patients over 75 years are more susceptible to statin-induced myopathy due to reduced CYP enzyme activity and lower lean muscle mass. Starting rosuvastatin at 5 mg daily in this group and advancing slowly is the standard approach. The ACC/AHA 2018 guidelines note that in adults over 75 years with ASCVD, a clinician-patient risk discussion should precede statin initiation or intensification.

Evolocumab pharmacokinetics are not meaningfully altered by age. In FOURIER, the relative risk reduction was consistent across age subgroups including patients over 75.

Patients With Chronic Kidney Disease

Rosuvastatin 40 mg is contraindicated when eGFR falls below 30 mL/min/1.73m², per FDA labeling. The maximum recommended dose in that population is 10 mg daily. Evolocumab requires no renal dose adjustment through any stage of CKD, including dialysis-dependent patients. Evolocumab renal pharmacokinetics are summarized in the FDA prescribing information.

Head-to-Head Summary Table

| Feature | Rosuvastatin (Crestor) | Evolocumab (Repatha) | |---|---|---| | Route | Oral daily | SC injection q2w or monthly | | LDL reduction | 45 to 63% | 59 to 62% (on top of statin) | | Time to full effect | 8 to 12 weeks (titration) | 2 weeks (no titration) | | Myalgia rate | 7 to 10% (PRIMO registry) | 2.6% (FOURIER) | | Outcomes data | JUPITER (primary prevention) | FOURIER (secondary prevention) | | Annual cost (US) | $20 to 40 (generic) | ~$7,200 (list price) | | Renal restriction | Cap 10 mg if eGFR <30 | None | | Prior auth required | No | Yes (most payers) |